Related Experiment Video

Updated: Jul 28, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

[Experience with the superselective third-generation beta-adrenoblocker nebivolol used to treat patients with prior

N A Bichan, E F Bykova, Ia A Gorbatovskiĭ

    Klinicheskaia Meditsina
    |October 8, 2004
    PubMed

    Insights

    Nebivolol therapy in patients with prior myocardial infarction (MI) improved exercise tolerance and quality of life. This study found nebivolol safe and effective for long-term MI patient management.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Research

    Context:

    • Myocardial infarction (MI) survivors with preserved ejection fraction (≥40%) often face long-term challenges.
    • Evaluating the impact of beta-blockers on functional capacity and quality of life (LQ) in post-MI patients is crucial.
    • Nebivolol, a selective beta-1 blocker, is investigated for its efficacy and safety in this population.

    Purpose:

    • To assess the long-term effectiveness and safety of nebivolol therapy in patients with a history of MI.
    • To evaluate the effects of nebivolol on patients' quality of life, including psychological and functional parameters.
    • To determine nebivolol's impact on cardiac remodeling and clinical outcomes post-MI.

    Summary:

    • A 1-year study involving 71 post-MI patients (ejection fraction ≥40%) treated with nebivolol (mean dose 3.66 mg/day).
    • Significant improvements observed in exercise tolerance (p < 0.001), return to work (97%), and antiarrhythmic effects (66.7%).
    • Nebivolol showed low mortality (1.4%), few cardiovascular events (4.2%), good tolerability, and improved quality of life metrics (reduced anxiety, improved personality scores).

    Impact:

    • Nebivolol demonstrated high effectiveness and safety in prolonged therapy for post-MI patients.
    • The drug exhibited no cardiodepressive activity and positively influenced patients' quality of life.
    • Nebivolol offers a promising therapeutic option for managing patients after myocardial infarction, enhancing both clinical and psychosocial outcomes.

    More Related Videos

    The Intra-Aortic Balloon Pump06:13

    The Intra-Aortic Balloon Pump

    Published on: February 5, 2021

    Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

    Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

    Published on: September 15, 2023

    Related Concept Videos

    Adrenergic Antagonists: Chemistry and Classification of &#946;-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
    Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Types of &#946;-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Heart Failure Drugs: &#946;-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...